SCHEMBL25554302

SCHEMBL25554302

Cc1cc(Oc2cc(C#N)ccc2-c2ccc(C(O)C(C)(C)N)cn2)cc(N2CCOCC2)n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 10/20 0.40
MTOR P42345 7/20 0.40
AKT1 P31749 6/20 0.40
PIK3C3 Q8NEB9 1/20 0.40
LMNA P02545 1/20 0.39
ADORA2A P29274 1/20 0.34
PDE4D Q08499 1/20 0.33
MAPT P10636 1/20 0.33
AURKA O14965 1/20 0.33
KIT P10721 1/20 0.33
FLT3 P36888 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
SOS1 Q07889 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CB P42338 1/20 0.33
ALDH1A1 P00352 1/20 0.33
EGLN1 Q9GZT9 1/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25554531 0.89 PIK3CA (0.41) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25559636 0.89 PIK3CA (0.41) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25554519 0.88 PIK3CA (0.43) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25554472 0.88 PIK3CA (0.43) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25554498 0.87 LMNA (0.41) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25554470 0.87 PIK3CA (0.43) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25554494 0.86 PIK3CA (0.40) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25554507 0.86 PIK3CA (0.40) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25555942 0.85 PIK3CA (0.41) PIK3CAMTORAKT1PIK3C3LMNA
SCHEMBL25555944 0.85 PIK3CA (0.41) PIK3CAMTORAKT1PIK3C3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE ARRB1, NR3C2, TRPC6 PIK3CA 3474/4885MTOR 616/4885AKT1 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.